P08.09 Axitinib for the treatment of patients with recurrent glioblastoma, final results from a randomized phase II clinical trial

ABSTRACT: Abstract

Background:

vascular endothelial growth factor receptor (VEGFR) signal transduction mediates glioblastoma (GB) associated neo-angiogenesis. The AXIG trial (NCT01562197) is a randomized clinical trial that initially investigated the activity of axitinib as a monotherapy (AXI-arm) versus physicians best alternative choice of therapy (Duerinck et al. JNO Mar 2016) and following amendment versus axitinib plus lomustine (Duerinck et al. ASCO AM 2016).

Methods:

an updated pooled analysis was made of the clinical outcome of all patients who initiated treatment with axitinib mono-therapy or axitinib in combination with lomustine in the AXIG trial.

Results:

between August 2011 and July 2015, a total of 78 pts were enrolled in the trial and initiated treatment wit

SUBMITTER: Duerinck J 

PROVIDER: S-EPMC5782638 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature